Ticagrelor

Drug Profile

Ticagrelor

Alternative Names: AR-C 126532; AZD-6140; Brilinta; Brilique

Latest Information Update: 27 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; The Medicines Company; Uppsala University; Vanderbilt University
  • Class Antithrombotics; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Cardiovascular disorders; Stroke
  • Phase II Abdominal aortic aneurysm; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 12 May 2017 Phase-I clinical trials in Sickle cell anaemia (In volunteers) in Germany (PO) (NCT03126695)
  • 26 Apr 2017 AstraZeneca plans a phase I trial in volunteers in Germany (NCT03126695)
  • 27 Feb 2017 AstraZeneca completes a phase II trial in Sickle cell anaemia (In children, In adolescents) in USA, Canada, Kenya, Lebanon, Italy, South Africa and the United Kingdom (NCT02214121)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top